Ultragenyx Pharma (RARE) Misses Q2 EPS by 20c
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($0.83), $0.20 worse than the analyst estimate of ($0.63).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.